FWM
AXSM icon

Focused Wealth Management’s Axsome Therapeutics AXSM Stock Holding History

Focused Wealth Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,050
Closed -$21K – 709
2019
Q3 		$21K Buy
+1,050
New +$27K 0.01% 381
2019
Q2 		– Sell
-4,500
Closed -$90.2K – 728
2019
Q1 		$64K Buy
+4,500
New +$41.8K 0.02% 269

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Focused Wealth Management's AXSM Position: Q4 2019 in Review

Focused Wealth Management sold out of Axsome Therapeutics (AXSM) in Q4 2019, closing a stake of 1,050 shares — an estimated $21K sold.

Focused Wealth Management first reported a position in AXSM in Q1 2019 and held it in 2 quarters. The position peaked at $64K in Q1 2019. 169 funds tracked by Wall St. Rank hold AXSM as of Q4 2019.

  • Focused Wealth Management reported no remaining Axsome Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Focused Wealth Management sold 1,050 Axsome Therapeutics shares in Q4 2019, an estimated $21K.
  • Focused Wealth Management first reported a position in Axsome Therapeutics in Q1 2019 and held it in 2 quarters.
  • Focused Wealth Management's Axsome Therapeutics position peaked at $64K in Q1 2019.
  • 169 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q4 2019.

Based on Focused Wealth Management's 13F filing for Q4 2019, filed 21 Jan 2020.